Skip to content

Study · Systematic review · 2011

9 results

[Treatment with interferon and thymosin alpha-1 versus interferon monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis].

Mao HY, Shi TD

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology1 Jan 2011Cited by 5 (Europe PMC)

PMID21272455 (opens in a new tab)DOI10.3760/cma.j.issn.1007-3418.2011.01.009 (opens in a new tab)PepBankPUB-21272455
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBV-DNA negative rate than interferon alone at the end of treatment.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon gave more patients with undetectable HBV-DNA at the end of treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBV-DNA negative rate at end of treatment
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBV-DNA negative rate
    54.9%
    combination, end of treatment
    HBV-DNA negative rate
    36.3%
    interferon alone, end of treatment
    OR
    2.39
    end of treatment
    95% CI
    1.64 to 3.49
    end of treatment

    Source sentences

    Summary
    HBV-DNA negative rate (54.9% vs 36.3%, OR=2.39, 95% CI=1.64-3.49, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  2. 02HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBV-DNA negative rate than interferon alone at follow-up.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon gave more patients with undetectable HBV-DNA at follow-up.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBV-DNA negative rate at follow-up
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBV-DNA negative rate
    58.6%
    combination, follow-up
    HBV-DNA negative rate
    30.7%
    interferon alone, follow-up
    OR
    3.68
    follow-up
    95% CI
    2.51 to 5.41
    follow-up

    Source sentences

    Summary
    58.6% vs 30.7%, OR=3.68, 95% CI=2.51-5.41, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  3. 03HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher ALT normalization rate than interferon alone at the end of treatment.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon gave more patients with normal ALT at the end of treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseALT normalization rate at end of treatment
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    ALT normalization rate
    74.5%
    combination, end of treatment
    ALT normalization rate
    60.9%
    interferon alone, end of treatment
    OR
    1.94
    end of treatment
    95% CI
    1.26 to 3
    end of treatment

    Source sentences

    Summary
    ALT normalization rate (74.5% vs 60.9%, OR=1.94, 95% CI=1.26-3.00, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  4. 04HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher ALT normalization rate than interferon alone at follow-up.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon gave more patients with normal ALT at follow-up.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseALT normalization rate at follow-up
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated

    Measurements

    ALT normalization rate
    74%
    combination, follow-up
    ALT normalization rate
    55.6%
    interferon alone, follow-up
    OR
    2.36
    follow-up
    95% CI
    1.54 to 3.62
    follow-up

    Source sentences

    Summary
    74.0% vs 55.6%, OR=2.36, 95% CI=1.54-3.62, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  5. 05HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBeAg loss rate than interferon alone at the end of treatment.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon led more patients to lose HBeAg at the end of treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg loss rate at end of treatment
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBeAg loss rate
    56.9%
    combination, end of treatment
    HBeAg loss rate
    36.7%
    interferon alone, end of treatment
    OR
    2.38
    end of treatment
    95% CI
    1.61 to 3.51
    end of treatment

    Source sentences

    Summary
    HBeAg loss rate (56.9% vs 36.7%, OR=2.38, 95% CI=1.61-3.51, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  6. 06HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBeAg loss rate than interferon alone at follow-up.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon led more patients to lose HBeAg at follow-up.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg loss rate at follow-up
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBeAg loss rate
    62.2%
    combination, follow-up
    HBeAg loss rate
    33.2%
    interferon alone, follow-up
    OR
    3.42
    follow-up
    95% CI
    2.31 to 5.06
    follow-up

    Source sentences

    Summary
    62.2% vs 33.2%, OR=3.42, 95% CI=2.31-5.06, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  7. 07HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBeAg seroconversion rate than interferon alone at the end of treatment.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon led more patients to seroconvert at the end of treatment.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg seroconversion rate at end of treatment
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBeAg seroconversion rate
    40.1%
    combination, end of treatment
    HBeAg seroconversion rate
    29%
    interferon alone, end of treatment
    OR
    1.65
    end of treatment
    95% CI
    1.1 to 2.47
    end of treatment

    Source sentences

    Summary
    HBeAg seroconversion rate (40.1% vs 29.0%, OR=1.65, 95% CI=1.10-2.47, P value is less than 0.05
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  8. 08HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBeAg seroconversion rate than interferon alone at follow-up.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon led more patients to seroconvert at follow-up.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBeAg seroconversion rate at follow-up
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBeAg seroconversion rate
    47%
    combination, follow-up
    HBeAg seroconversion rate
    29.5%
    interferon alone, follow-up
    OR
    2.13
    follow-up
    95% CI
    1.43 to 3.16
    follow-up

    Source sentences

    Summary
    47.0% vs 29.5%, OR=2.13, 95% CI=1.43-3.16, P value is less than 0.01
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).
  9. 09HumanSystematic reviewEfficacy outcome

    In HBeAg positive chronic hepatitis B, interferon plus thymosin alpha‑1 gave a higher HBsAg loss rate than interferon alone at follow-up only.

    In plain wordsIn HBeAg positive chronic hepatitis B, adding thymosin alpha‑1 to interferon led more patients to lose HBsAg, at follow-up only.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseHBsAg loss rate at follow-up
    Study

    n: not reported in source

    Comparator
    Interferon monotherapy
    Outcome group
    Antiviral activity · Infection
    Studied dose
    Dose not stated

    Measurements

    HBsAg loss rate
    9.8%
    combination, follow-up
    HBsAg loss rate
    3.7%
    interferon alone, follow-up
    OR
    2.92
    follow-up
    95% CI
    1.09 to 7.76
    follow-up

    Source sentences

    Summary
    HBsAg loss rate of the combination therapy group was significantly higher than that of the monotherapy group only at the end of the follow-up (9.8% vs 3.7%, OR=2.92, 95% CI=1.09-7.76, P value is less than 0.05
    2 context sentences
    Summary · context
    To compare the efficacy of interferon and thymosin alpha-1 combination therapy with interferon monotherapy for HBeAg positive chronic hepatitis B.
    Summary · context
    Seven randomized controlled trials were included(535 patients in total).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 17:28 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.